GreeceTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.11 (0.11–0.12) 1 (0.96–1.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.02)
Prevalence  (includes HIV+TB) 0.67 (0.28–1.2) 6 (2.6–11)
Incidence  (includes HIV+TB) 0.53 (0.46–0.6) 4.8 (4.2–5.4)
Incidence (HIV+TB only) 0.016 (0.012–0.019) 0.14 (0.11–0.18)
         
Case detection, all forms (%) 92 (81–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.5 (0.04–8) 9.1 (0.23–41)
MDR-TB cases among notified pulmonary
TB cases
6 (0–33) 3 (0–14)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 354   0
Pulmonary, clinically diagnosed 51   0
Extrapulmonary 79   0
       
Total new and relapse 484    
Previously treated, excluding relapses 35    
Total cases notified 519    
Among 482 new and relapse cases:
9 (2%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 120 (34%) 12 (34%) 145
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment ***      
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013    
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available?  
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-06 Data: www.who.int/tb/data